Adjuvant Pembrolizumab Beneficial in Stage III Melanoma

Share this content:
Adjuvant Pembrolizumab Beneficial in Stage III Melanoma
Adjuvant Pembrolizumab Beneficial in Stage III Melanoma

MONDAY, April 16, 2018 (HealthDay News) -- Pembrolizumab is associated with significantly longer recurrence-free survival than placebo as adjuvant therapy for high-risk stage III melanoma, according to a study published online April 15 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the American Association for Cancer Research, held from April 14 to 18 in Chicago.

Alexander M.M. Eggermont, M.D., Ph.D., from Gustave Roussy Cancer Campus Grand Paris, and colleagues randomized patients with completely resected stage III melanoma to receive 200 mg pembrolizumab (514 patients) or placebo (505 patients) intravenously every three weeks for 18 doses.

The researchers found that in the overall intention-to-treat population, pembrolizumab correlated with significantly longer recurrence-free survival than placebo at a median follow-up of 15 months (one-year rate of recurrence-free survival, 75.4 versus 61.0 percent; hazard ratio for recurrence or death, 0.57); the correlation was also seen in the subgroup of 853 patients with programmed death-1 ligand-positive tumors (one-year rate of recurrence-free survival, 77.1 versus 62.6 percent; hazard ratio, 0.54). Overall, 14.7 and 3.4 percent of patients in the pembrolizumab and placebo groups, respectively, had adverse events of grades 3 to 5 that were related to the trial regimen. One treatment-related death occurred in the pembrolizumab group.

"As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every three weeks for up to one year resulted in significantly longer recurrence-free survival than placebo, with no new toxic effects identified," the authors write.

One author disclosed financial ties to the pharmaceutical industry. The study was sponsored by Merck, the manufacturer of pembrolizumab.

Abstract/Full Text
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves First Customizable Insulin Pump

FDA Approves First Customizable Insulin Pump

Product works by delivering insulin under the skin at set or variable rates

Sepsis Common in Terminal Hospitalizations, Discharges

Sepsis Common in Terminal Hospitalizations, Discharges

Most common underlying causes of death in sepsis are solid and hematologic cancers, chronic heart disease

Fewer Older Men Assessed, Treated for Osteoporosis

Fewer Older Men Assessed, Treated for Osteoporosis

Fewer older men than women, even with higher risk, undergo DXA screening, 25(OH)D measurement

is free, fast, and customized just for you!




Already a member?

Sign In Now »